Pharmaceutical product

• Rrd Selected As Development Partner for Nih Therapeutics for Rare and Neglected Diseases Program

ROCKVILLE, Md., Jan. 24, 2011 /PRNewswire/ -- RRD International, a strategy-driven biotech and pharmaceutical product development company, announced today that it has entered into a partnership with the National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program as a regulatory support and development partner. The RRD and TRND partnership will focus on two rare disease drug development projects: Hereditary Inclusion Body Myopathy (HIBM), a rare adult-onset neuromuscular disorder and Niemann Pick type C1 Disease (NPC1), a rare neurodegenerative genetic disease.

• U.S. Newswire
• January 24, 2011

• Foreign-Trade Zone 59-Lincoln, Nebraska, Application for Temporary/Interim Manufacturing Authority, Novartis Consumer Health, Inc. (Pharmaceutical Product Manufacturing), Lincoln, NE

• Federal Register Nbr. 77 FR 4758, January 31, 2012
• Notices
• Foreign Trade Zones Board

• The applicability of Twombly and Iqbal to pharmaceutical product liability litigation.

This article originally appeared in the November 2009 Drug, Device and Biotechnology Committee Newsletter. ********** Since the adoption of the Fe...

• Defense Counsel Journal
• Vol. 77 Nbr. 1, January 2010

• Successful Market Education Strategies and Tactics for New Pharmaceutical Product Launches in the Oncology Therapeutic Area

CHAPEL HILL, N.C., Dec. 2, 2011 /PRNewswire/ -- As the pharmaceutical industry continues to win new approvals and indications for cancer therapies, the global oncology market is on track to reach $75 billion by 2013. While the U.S. dominates the oncology market, it is also one of the most daunting countries for new products to penetrate. Faced with an increasingly challenging marketplace, pharmaceutical and biotech companies have come to recognize the value of market education in winning support among the key oncology stakeholders that can help new products gain a foothold.

• U.S. Newswire
• December 02, 2011

• The Product Liability of Pharmaceutical Companies.

The product liability arising due to the use of pharmaceuticals is a very sensitive issue in comparison with any other kind of product liability, sinc...

• Mondaq Business Briefing
• Nbr. 2010, January 2010

• Law Offices of Howard G. Smith LLP Continues Investigation of Pharmaceutical Product Development, Inc.

LOS ANGELES -- Law Offices of Howard G. Smithis continuing its investigation of potential claims against the Board of Directors of Pharmaceutical Prod...

• Business Wire
• October 07, 2011

• The evolving landscape for pharmaceutical product liability litigation in Canada.

ONLY a handful of pharmaceutical product liability cases have been tried in Canada, with the leading case being a decision from the mid-1980s involvin...

• Defense Counsel Journal
• Vol. 73 Nbr. 3, July 2006

• Life After Levine: The Future Of The Preemption Defense In Pharmaceutical Product Liability Litigation

On March 4, 2009, the U.S. Supreme Court delivered its highly anticipated decision in Wyeth v. Levine, upholding the plaintiff's $7.4 million product ...

• Mondaq Business Briefing
• United States Law Articles in English

• Mass tort treatment of pharmaceutical product liability cases in England.

ENGLAND was one of the first European Union ("EU") countries to introduce specific procedural provisions for "group actions" seeking recovery of damag...

• Defense Counsel Journal
• Vol. 73 Nbr. 3, July 2006

• Schedules of Controlled Substances: Exempted Prescription Product; River Edge Pharmaceutical, Servira

• FR, March 30, 2010
• Proposed rules
• Drug Enforcement Administration